A phase i study of combination chemotherapy using TS-1 and weekly paclitaxel for advanced gastric cancer
Fujiwara, Y.; Fujita, J.; Kan, K.; Tsukahara, K.; Takiguchi, S.; Miyata, H.; Yasuda, T.; Doki, Y.; Monden, M.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 33(1): 45-48
2006
ISSN/ISBN: 0385-0684 PMID: 16410697 Document Number: 596119
The safety of chemotherapy combining TS-1 and weekly paclitaxel for the treatment of unresectable and recurrent gastric cancer was evaluated in this study. Paclitaxel was administered by intravenous drip infusion at a starting dose (level 1) of 50 mg/m2 on days 1, 8, and 15. TS-1 was administered orally at a dose of 40 mg/m2twice a day for 2 weeks (days 1-14) followed by 2 weeks rest. A total of 9 patients were enrolled in this study. Two out of 6 patients treated with level 1 suffered from leukocytopenia and neutropenia, which were determined as dose-limiting toxicity (DLT). Three patients were treated with level 2, in which the dose of paclitaxel was increased up to 60 mg/m2. One of 3 patients suffered from grade 3 diarrhea and one patient from grade 4 leukocytopenia, eutrocytopenia, anemia, and stomatitis, which were determined as DLT. According to these results,level 1 of this regimen was recommended as a safe treatment for gastric cancer patients. A phase II study will be performed to evaluate the efficacy of the combination chemotherapy.